No. Title Date 6 GI Innovation Signs MOU with Agilent for Biomarker Profiling Collaboration in Phase 1/2 Study of Cancer Immunotherapy GI-101 2020-10-07 5 GI Innovation, Immuno-oncology GI-101 • Keytruda® Combined Therapy Joint Clinical Agreement with MSD 2020-07-22 4 GI Innovation, global out-licensing worth 1.4 trillion won to YUHAN 2020-07-01 3 GI Innovation, signs MOU in non-exclusive license on immuno-oncology candidate sequence with Y-biologics 2020-06-22 2 GI Innovation, announces cooperation development with IVI on Covid-19 vaccine immune adjuvant 2020-04-09 1 GI Innovation, licensed-out for bispecific fusion protein immuno-oncology worth of 900 billion won to Simcere Corp. 2019-11-28 Title Content < 1 2 3 4 >
